Eris Lifesciences Ltd

1 year ago 161

Eris Lifesciences Ltd is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model. Ranked #21 in the IPM, Eris has established a leading presence in its core cardio-metabolic franchise in just 15 years from inception. Eris is also successfully diversifying its business with 3 emerging therapies (Dermatology, Neuropsychiatry and Gynaecology) accounting for 20% of its revenue and growing at > 25% p.a.

We began our journey 15 years ago in 2007 with the vision to make a meaningful impact in the management of chronic lifestyle related diseases. Today Chronic and Sub-chronic therapies account for ~ 90% of our revenue, and our product range spans ~ 90% of India’s Rs. 55,000+ crore chronic care market. Our business model is pivoted around specialist/ super specialist doctors and high end consulting physicians. We consistently endeavour to channel the advantages of cutting-edge medical knowledge to aid our clinicians and patients with better disease management options and outcomes.

Our market engagement consists of two pillars – (i) Patient Care Initiatives (PCI), and (ii) India-Centric Studies. Through our PCI platform, we bring cutting edge diagnosis and monitoring technologies to patients. The insights from these interventions are immensely useful to our physicians in managing the health outcomes of their patients. Examples of such interventions include Ambulatory Blood Pressure Monitoring (ABPMs), Continuous Glucose Monitoring (CGMs), Holter Devices, Sleep Studies, etc. Our second engagement pillar, India-centric Studies was born out of the imperative to generate and use India-centric data in the diagnosis and management of cardio-metabolic conditions. In FY21 the results of our first such study – The India Heart Study (IHS) – were published in the Journal of Hypertension, which is the official journal of the European Society of Hypertension. On the back of the success of the IHS, we recently concluded the India Diabetes Study (IDS), the results of which were published in April 2022 in the Public Library of Science (PLOS) journal.

Take me to the Website
SAFETY TIPS FOR BUYER & SELLER
Meet seller at a public place | Check the item before you buy. | Pay only after collecting the item.
TRADEMARK DISCLAIMER
All trademarks, logos and brand names are the property of their respective owners.